Nuvectis Pharma (NVCT) Operating Income (2021 - 2026)
Nuvectis Pharma (NVCT) posted Operating Income of -$6.3 million for Q1 2026, up 17.82% sequentially from -$7.6 million in Q4 2025, and down 12.43% YoY from -$7.1 million in Q1 2025.
Nuvectis Pharma (NVCT) Operating Income (2021 - 2026) Analysis & Trends
Nuvectis Pharma has reported Operating Income for 6 years, with the latest figure at -$6.3 million in Q1 2026.
- Quarterly Operating Income fell 12.43% year-over-year to -$6.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$28.3 million (down 34.48% YoY) and the FY2025 annual result came in at -$27.6 million, down 38.93% from the prior year.
- Operating Income climbed to -$6.3 million in Q1 2026 per NVCT's latest filing, from -$7.6 million in the prior quarter.
- Over five years, Operating Income peaked at -$2.9 million in Q1 2022 and troughed at -$7.8 million in Q3 2025.
- A 5-year average of -$5.6 million and a median of -$5.9 million in 2022 frame the typical range for Operating Income.
- The widest YoY moves for Operating Income: up 39.83% in 2022, down 199.25% in 2022.
- Over 5 years, Operating Income stood at -$6.8 million in 2022, then fell by 1.3% to -$6.9 million in 2023, then advanced by 6.07% to -$6.4 million in 2024, then dropped by 18.11% to -$7.6 million in 2025, then rose by 17.82% to -$6.3 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$6.3 million, -$7.6 million, and -$7.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Nuvectis Pharma | 506.13 Mn | 506.13 Mn | - | -7.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -7.20 Mn |
| Mar 31, 2026 | -6.26 Mn |
| Dec 31, 2025 | -7.62 Mn |
| Sep 30, 2025 | -7.79 Mn |
| Jun 30, 2025 | -6.60 Mn |
| Mar 31, 2025 | -5.57 Mn |
| Dec 31, 2024 | -6.45 Mn |
| Sep 30, 2024 | -4.36 Mn |
| Jun 30, 2024 | -4.64 Mn |
| Mar 31, 2024 | -4.40 Mn |
| Dec 31, 2023 | -6.87 Mn |
| Sep 30, 2023 | -6.16 Mn |
| Jun 30, 2023 | -5.77 Mn |
| Mar 31, 2023 | -4.10 Mn |
| Dec 31, 2022 | -6.78 Mn |
| Sep 30, 2022 | -5.94 Mn |
| Jun 30, 2022 | -3.57 Mn |
| Mar 31, 2022 | -2.95 Mn |
| Dec 31, 2021 | -2.27 Mn |
| Sep 30, 2021 | -4.67 Mn |